NEW YORK – NanoView Biosciences said on Wednesday that it has signed an exclusive agreement with Quantum Design to distribute its ExoView platform in China.
The research-use-only ExoView platform is an antibody labeling and imaging-based tool that offers high-resolution sizing, counting, and phenotyping of extracellular vesicles and viral vectors. Boston-based NanoView noted that the platform requires low sample input, no extensive sample preparation or purification, and minimal hands-on time.
"We are excited to work with Quantum Design China, and further expand our distribution relationship with Quantum Design International," Jerry Williamson, CEO of NanoView, said in a statement. "Accurate extracellular vesicle characterization is a critical step forward in precision nanomedicine, and our goal is to enable that progress with our one-of-a-kind products, which allow researchers to better understand the function and utility of these important biological nanoparticles."
Financial details of the agreement were not disclosed.
"We are pleased to offer customers in China access to the ExoView platform, which allows scientists the unprecedented ability to accurately identify and characterize extracellular vesicles, including exosomes and viruses," Lamber Cao, general manager of Quantum Design China, said in a statement.
NanoView previously signed a distribution agreement with Isaza Scientific in February to distribute ExoView in Spain and Portugal.